Literature DB >> 21629132

Establishment of a primary pleomorphic xanthoastrocytoma cell line: in vitro responsiveness to some chemotherapeutics.

Emin Umit Bagriacik1, Mustafa Kemali Baykaner, Melek Yaman, Gizem Sivrikaya, Emre Durdağ, Hakan Emmez, Gökçe Öztürk Fincan, Alp Özgün Börcek, Ahmet Eren Seçen, Sevim Ercan.   

Abstract

BACKGROUND: Anaplastic pleomorphic xanthoastrocytoma is an aggressively growing, malignant, and eventually fatal tumor of the central nervous system. Testing chemotherapeutic drug sensitivity under in vitro conditions would be a useful strategy to determine sensitive or resistant drugs for fatal brain cancers.
OBJECTIVE: To establish primary cell cultures of excised tumor tissue from pleomorphic xanthoastrocytoma-bearing patients and to test their sensitivity against various anticancer chemotherapy drugs.
METHODS: Prepared suspensions of the excised tumor tissue from a patient who had a recurrent grade 3 pleomorphic xanthoastrocytoma was cultured in culture dishes until cells began to grow. Immunofluorescent and immunohistochemical visualizations were performed using confocal and light microscopy. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay in comparison with ³H-thymidine incorporation assay was used to test cellular toxicity of several anticancer drugs.
RESULTS: We established vigorously growing primary cells of the tumor. Drug sensitivity testing was conducted successfully.
CONCLUSION: Primary cell cultures of surgically removed tumor tissues may be useful in studies of cancer biology and chemotherapeutic drug sensitivity for recurrent malignant brain tumors, particularly for anaplastic pleomorphic xanthoastrocytoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21629132     DOI: 10.1227/NEU.0b013e3182262c5b

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  5 in total

1.  Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.

Authors:  Cristiane M Ida; Fausto J Rodriguez; Peter C Burger; Alissa A Caron; Sarah M Jenkins; Grant M Spears; Dawn L Aranguren; Daniel H Lachance; Caterina Giannini
Journal:  Brain Pathol       Date:  2014-12-05       Impact factor: 6.508

2.  Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma.

Authors:  Raees Tonse; Tejpal Gupta; Sridhar Epari; Jayant Goda Shastri; Mamta Gurav; Nazia Bano; Rakesh Jalali
Journal:  J Neurooncol       Date:  2017-11-16       Impact factor: 4.130

3.  Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.

Authors:  Eric M Thompson; Daniel Landi; David Ashley; Stephen T Keir; Darell Bigner
Journal:  J Neurooncol       Date:  2018-08-17       Impact factor: 4.130

4.  Clinicopathological and imaging features of lipoastrocytoma: Case report.

Authors:  Laxminadh Sivaraju; Saritha Aryan; Nandita Ghosal; Alangar S Hegde
Journal:  Neuroradiol J       Date:  2017-06-23

Review 5.  Implications and limitations of cellular reprogramming for psychiatric drug development.

Authors:  Brian T D Tobe; Michael G Brandel; Jeffrey S Nye; Evan Y Snyder
Journal:  Exp Mol Med       Date:  2013-11-15       Impact factor: 8.718

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.